A 6-month Multicenter, Randomized, Double-masked Phase IIIb-study Comparing the Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO)
Latest Information Update: 30 Jul 2021
At a glance
- Drugs Ranibizumab (Primary) ; Dexamethasone
- Indications Branch retinal vein occlusion; Retinal oedema
- Focus Registrational; Therapeutic Use
- Acronyms COMRADE-B
- Sponsors Novartis
Most Recent Events
- 03 Jun 2014 New source identified and integrated, European Clinical Trials Database record (EudraCT2011-001019-30).
- 03 Jun 2014 New trial record
- 12 May 2014 Primary endpoint 'Best-corrected-visual-acuity' has been met according to the Novartis media release.